Dekkers, Bart G. J. published the artcileRelevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat, Related Products of catalysis-chemistry, the publication is AIDS (London, United Kingdom) (2019), 33(6), 1100-1102, database is CAplus and MEDLINE.
Reporting on the serol. response to syphilis treatment with penicillin benzathine or doxycycline in patients with HIV following a manufacturing shortfall of penicillin benzathine. Discomfort of these injections can be reduced by replacing part of the solvent by a lidocaine (lignocaine) solution To enhance exposure to antiretroviral drugs, such as atazanavir, darunavir and elvitegravir, ritonavir and cobicistat are used as boosters in combined antiretroviral therapy. Ritonavir and cobicistat inhibit CYP3A4, resulting in an increased exposure (increased area under the curve) , increased maximum concentration (Cmax) and increased half-life 1/2 of antiretroviral drugs that are substrates of CYP3A4. Drug-drug interactions between ritonavir or cobicistat and lidocaine have been suggested to increase lidocaine exposure by more than three-fold complicating treatment with benzylpenicillin benzathine as this interaction may lead to higher plasma lidocaine levels and adverse effects, including neurol. and cardiac side effects.
AIDS (London, United Kingdom) published new progress about 140-28-3. 140-28-3 belongs to catalysis-chemistry, auxiliary class Benzenes, name is N1,N2-Dibenzylethane-1,2-diamine, and the molecular formula is C16H20N2, Related Products of catalysis-chemistry.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia